Showing 1701-1710 of 2099 results for "".
- Merz Aesthetics’ Belotero Balance (+) Receives FDA Approval for Infraorbital Hollowshttps://modernaesthetics.com/news/merz-aesthetics-belotero-balance-receives-fda-approval-for-infraorbital-hollows/2473500/The U.S. Food and Drug Administration (FDA) approved Merz Aesthetics’ Belotero Balance (+) for improvement of the infraorbital hollow (IOH) in adults over the age of 21. This approval stems from positive pivotal study results demonstrating the efficacy and safety of Belotero
- Industry Vet Aaron Green Joins RepeatMDhttps://modernaesthetics.com/news/industry-vet-aaron-green-joins-repeatmd/2473498/Aaron Green is RepeatMD’s new Vice President of Business Development. RepeatMD is a mobile shopping platform that integrates ecommerce and fintech solutions, providing aesthetic and wellness practices with a personalized shopping experience for their patients. &quo
- Will Platysma Prominence Be the Next Nod for BOTOX Cosmetic?https://modernaesthetics.com/news/will-platysma-prominence-be-the-next-nod-for-botox-cosmetic/2473497/Allergan Aesthetics’ BOTOX Cosmetic met all primary and secondary endpoints for the treatment of moderate to severe platysma prominence associated with platysma muscle activity, according to topline results from the second of three Phase 3 studies. The multicenter, randomized
- BOTOX Cosmetic, IFundWomen Launch Crowdfunding Campaignshttps://modernaesthetics.com/news/botox-cosmetic-and-ifundwomen-launch-crowdfunding-campaigns/2473493/Allergan Aesthetics announced the next chapter of the BOTOX Cosmetic and IFundWomen grant program with the launch of crowdfunding campaigns for the women entrepreneurs. The brand
- Cutera Introduces Secret DUOhttps://modernaesthetics.com/news/cutera-introduces-secret-duo/2473490/Cutera, Inc. is launching Secret DUO, a skin resurfacing and revitalization platform that utilizes dual non-ablative fractional technologies. Each modality can be used individually or in combination to target a wide range of aesthetic indications. Secret DUO is equipped
- Why I Sold: Dr. Brian Biesman Joins MedSpa Partnershttps://modernaesthetics.com/news/why-i-sold-dr-brian-biesman-joins-medspa-partners/2473487/Nashville-based oculofacial plastic surgeon Dr. Brian Biesman is joining MedSpa Partners (MSP) Inc. "I'm excited for us to join such a talented and accomplished group of practices and practitioners. We have always prided ourselves on our commitment to rigorously
- Angela Hildebrand Named General Manager at SkinCeuticals USAhttps://modernaesthetics.com/news/angela-hildebrand-named-general-manager-at-skinceuticals-usa/2473485/Angela Hildebrand is SkinCeuticals’ new General Manager and Amy Sloan is the Senior Vice President of Business Strategy and Growth. "With their collective knowledge, expertise, and dedication to excellence, Angela and Amy's leadership are poised to tak
- Cutera, Inc. Appoints Jeff Jones as Chief Operating Officerhttps://modernaesthetics.com/news/cutera-inc-appoints-jeff-jones-as-chief-operating-officer/2473482/Jeff Jones is Cutera, Inc.’s new Chief Operating Officer, effective August 28, 2023. Mr. Jones will report directly to Taylor Harris, Cutera’s Chief Executive Officer, and will be responsible for end-to-end operations, including manufacturing, quality, supply chain, fi
- Dr. Ashley Brissette Is Clinique’s First Guiding Ophthalmologisthttps://modernaesthetics.com/news/nyc-ophthalmologist-dr-ashley-brissette-is-cliniques-first-guiding-ophthalmologist/2473481/NYC-based ophthalmologist Ashley Brissette, MD, MSc, FRCSC, is Clinique’s first guiding ophthalmologist. In the newly created role, Dr. Brissette will help educate consumers on the importance of eye safety, help guide the development of new products, and contribute to C
- Delnova Demonstrates Proof of Concept for ReViVoxhttps://modernaesthetics.com/news/delnova-demonstrates-proof-of-concept-for-revivox/2473478/Delnova’s ReViVox showed reversal or muscle paralysis or weakness in a small cohort of healthy subjects. ReViVox is being developed to resolve side effects that may result from botulinum neurotoxin treatments. In the proof-of-concept study, volunteer subj